cyrilzakka/clinical-trials huggingface dataset:
Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer

This trial studies how well standard and delayed fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) given after standard radiation and chemotherapy works in assessing patients with head and neck squamous cell cancer that has spread to other places in the body. Diagnostic procedures, such as PET/CT, use radioactive material, such as fludeoxyglucose F-18, to find and diagnose head and neck tumors and may help to find out how far the disease has spread.

PRIMARY OBJECTIVE:

I. To assess the optimal imaging time using FDG positron emission tomography (PET) with comparison between a standard of care 1-hour scan (early) and the research scan of 3-hours scan (delayed) post radiotracer administration that maximizes separation of activity between lesion and non-lesional parenchyma (measured as lesion/background \[L/B\] ratio) in patients with head and neck primary squamous cell carcinoma following chemoradiation treatment.

OUTLINE:

Patients receive fludeoxyglucose F-18 intravenously (IV) over 1 minute and undergo PET/CT at 70 and 180 minutes after injection at 12-14 weeks following standard chemoradiation (CRT) completion.

After completion of study, patients are followed up at 30 days and then periodically for up to 6 months.

Eligibility Criteria:
Inclusion Criteria:

* Adult with computed tomography (CT) or fludeoxyglucose F-18 (FDG) positron emission tomography (PET) findings of cervical nodal metastasis from a head and neck primary squamous cell carcinoma treated with definitive chemoradiation

Exclusion Criteria:

* Children
* No evidence of cervical nodal metastasis
* Active infection of the head and neck
* Known allergy to FDG, iodine or gadolinium-based contrast agents
* Blood glucose (\> 250 mg/dl)
* Pregnant women
Low Implanted Second Trimester Placenta and Placenta Previa

Placenta Previa is defined as a placenta implanted in the lower segment of the uterus, presenting ahead of the leading pole of the fetus (over or near the internal os). The prevalence of placenta previa has been estimated to be approximately 0.5% of all pregnancies, and this increase correlates to the elevated cesarean section rate . In Egypt, the prevalence of placenta previa is around 1.3% in Sohag Governorate and 1.5% in Aswan region according to.

Although various studies have tried to address risk factors associated with Placenta Previa development, the etiology of placenta previa still remains obscure. Several risk actors have been identified as strong contributors to placenta previa development. It is also a significant contributor to severe postpartum hemorrhage.Risk factors include; history of previous cesarean section, advanced maternal age, history of previous abortions, high parity and substance abuse during pregnancy (cigarette smoking), placental size (multiple pregnancy), endometrial damage (previous dilatation and curettage), uterine scars and pathology (previous myomectomy or endometritis), placental pathology (marginal cord insertions and succenturiate lobes), previous placental Previa, and curiously.


Eligibility Criteria:
Inclusion Criteria:

1. Pregnant women between 18-24 weeks.
2. Diagnosed to have low implanted placenta by ultrasound

Exclusion Criteria:

1. Patient refused to follow-up in our setting.
2. Patient refused to perform Trans-vaginal ultrasound in the second trimester of gestation.
Treatment Outcome Using Vivaer Stylus to Treat Nasal Airway Obstruction

This study evaluates subjective and objective measures of treatment outcome after using the Aerin Medical Vivaer™ Stylus to treat nasal obstruction

This is a non-significant risk, prospective, non-randomized study to evaluate subjective and objective measures of nasal obstruction both before and after treatment with the Vivaer Stylus. The Stylus is used to deliver radiofrequency (RF) energy to the nasal valve area to improve symptoms in those diagnosed with nasal airway obstruction.

Eligibility Criteria:
Inclusion Criteria:

* Complaints of nasal obstruction for at least 1 year
* Failed maximum medical therapy (4-6 weeks of steroids)
* Nasal Obstruction Symptom Evaluation (NOSE) score of ≥ 60 at Baseline
* Nasal valve is a primary or significant contributor to the subject's nasal obstruction as determined by the study investigator (based on clinical presentation, physical examination, nasal endoscopy, etc.) and the subject has a positive response to any of the following temporary measures (based on patient history or during office exam):

  1. Use of external nasal dilator strips (e.g., Breathe Right Strips)
  2. Q-Tip test (manual intranasal lateralization)
  3. Use of nasal stents
  4. Cottle Maneuver (manual lateral retraction of the cheek)

Exclusion Criteria:

* Prior surgical treatment of the nasal valve
* Rhinoplasty, septoplasty, inferior turbinate reduction or other surgical nasal procedures within the past three (3) months
* Severe and/or chronic sinusitis, recurrent sinusitis, or allergies leading to nasal obstruction and currently requiring oral corticosteroid therapy
* Severe case of any of the following: septal deviation, turbinate hypertrophy, polyps, or ptotic nose tip believed to be the primary contributor to the subject's nasal obstruction symptoms and warranting surgical intervention
* Known or suspected allergies or contraindications to the anesthetic agents and/or antibiotic medications to be used during the study procedure session
* Known or suspected to be pregnant, or is lactating
* Other medical conditions which in the opinion of the investigator could predispose the subject to poor wound healing or increased surgical risk
HE4 in the Diagnostic Approach of Endometrial Cancer in Patients With Postmenopausal Bleeding

This study aims to explore the sensitivity of an innovative marker, HE4, in the diagnosis approach of endometrial cancer in case of postmenopausal bleedings.

Endometrial cancer is the most common pelvic gynecological cancer in France, ranking 5th among cancers in women in terms of incidence.

The most frequent symptom is post-menopausal bleeding and is one of the primary reasons for consultation in gynecological emergencies.

The diagnosis of endometrial cancer is made by histological analysis of endometrial tissue taken during a surgical intervention. The latter is mostly reassuring.

These interventions are often performed in mild situations and there is currently no element to be sufficiently reassuring to avoid surgery.

At present, there is no biological marker used in current practice. In the population of patients with post-menopausal bleeding requiring surgical exploration for diagnosis, the pathology results are often reassuring. These procedures could have been avoided, especially as these patients often have numerous co-morbidities and these surgeries are therefore more risky. The appearance of a new tumour marker could be useful in the management of these patients and avoid many unnecessary and risky surgeries

This study aims to explore the sensitivity of an innovative marker, HE4, in the diagnosis approach of endometrial cancer in case of postmenopausal bleedings.

Eligibility Criteria:
Inclusion Criteria:

* Patient with postmenopausal bleeding
* Patient requiring hysteroscopy or hysterectomy
* No objection from the patient to participate in the study

Exclusion Criteria:

* Non-menopausal patient
* Patient under guardianship, curatorship or deprived of her freedom
* Patient with proven metastases on imaging
* Patient with a macroscopically suspicious cervix
* Patient presenting an ovarian cyst or an associated adnexal pathology
* Patient contraindicated for surgical treatment (therefore not eligible for pathological analysis)
* Patient who has already been treated with hormone therapy for breast cancer
* Patient who has already had surgery for this pathology, with a contributing anatomopathological result (we will therefore include patients who would not benefit from an operative hysteroscopy after performing a cornier® pipelle that does not allow a positive result)
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

The goal of this clinical trial is to evaluate the efficacy of Blinatumomab in pediatric patient with newly diagnosed acute B-Lymphoblastic leukemia with poor response to early chemotherapy, i.e. day 19 MRD ≥ 0.1% (low-risk) or day 19 MRD ≥ 0.01% (intermediate-risk). The main question is:

• If the flow cytometric MRD negative (\<0.01%) rate and the NGS- MRD negative (\<0.0001%) rate at the end of induction for patients received Blinatumomab will be superior to historical control (D46MRD in the CCCG-ALL2020 protocol).

Participants will:

* Take 14 days full dose Blinatumomab;
* With bone marrow evaluated before and after Blinatumomab treatment.


Eligibility Criteria:
Inclusion Criteria:

* Age older than 1 month to younger than 18 years.
* Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.
* Immunophenotyping: acute B-lymphoblastic leukemia;
* Meet one of the following situations:

A. Provisional low-risk: D19MRD ≥ 0.1%; B. Provisional intermediate-risk: D19MRD ≥ 0.01%;

* Subjects in the sytudy group or their guardians must be able to understand and accept the informed consent approved by the Ethics Committee

Exclusion Criteria:

* sIgM+;
* ALL evolved from chronic myeloid leukemia (CML);
* Down's syndrome, or major congenital or hereditary disease with organ dysfunction;
* Other secondary leukemias;
* CNS involvement;
* History of epilepsy; or convulsions within the last month;
* Known underlying congenital immunodeficiency or metabolic disease;
* Congenital heart disease with cardiac insufficiency;
* Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for \> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression);
* Initial diagnosis of high risk;
* D46MRD ≥1%.
The Effect Of Virtual Reality Glasses On Vital Signs And State Anxiety Level In Cancer Patients

This study was conducted as a non-randomized control group experimental study to determine the effect of virtual reality glasses on vital signs and state anxiety levels.

Purpose This study was conducted as a non-randomized control group experimental study to determine the effect of virtual reality glasses on vital signs and state anxiety levels in cancer patients receiving chemotherapy for the first time.

Methods and Sample The population of the study was composed of adult patients admitted to an oncology hospital in Ankara province with a diagnosis of stage I-II-III cancer to undergo chemotherapy treatment for the first time. The sample of the study consisted of 30 patients who were assigned to the intervention and control groups by the stratified sampling method (considering such characteristics as age, gender, marital status). The patient identification form, Spielberger state anxiety scale, patient opinion form, vital signs follow-up form, and virtual reality glasses were used to collect the data.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with stage 1,2,3 cancer
* Receive radiotherapy and chemotherapy for the first time
* Volunteer patients who agreed to participate

Exclusion Criteria:

-Patients outside the inclusion criteria
Determining the Age of First Acute Coronary Syndrome

The study aimed to evaluate the association between the obesity grade and the age of the first acute coronary syndrome (ACS). The effect of cardiovascular (CV) risk factors and the age of first ACS in patients with severe obesity was also examined. Consecutive patients with diagnosis of first episode of ACS were prospectively enrolled in 2014 to 2024.Cardiovascular risks of patients will be determined according to clinical and laboratory evaluation and patients were categorized by their body mass indices (BMI). Independent variables that effected the age of first ACS were examined by linear regression analysis

In the first stage, the first ACS diagnosis of the patients will be tried to be clarified. It will be tried to clarify whether the patients have had ACS before, according to their history, ecg echo and coronary angiography findings. Patients with previous ACS or uncertain ACS diagnosis will not be included in the study.

In the second stage, cardiovascular risk burdens of patients for whom the initial ACS diagnosis is clear will be revealed. Smoking, diabetes mellitus (DM), hypertension (HT), psychological stress, socio-economic status, migration history, cholesterol parameters will be determined. The duration and severity of these risk factors will be determined. In the final model, each risk factor will be examined in detail with its sub-tabs and the effect of each risk factor will be examined separately.

Eventually, a model will be developed that allows predicting the first ACS age. The shortcomings of this model and the narrow scope of the definition of the population will be determined and the direction will be determined for the studies that improve these points.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients with the diagnosis of the first acute coronary syndrome

Exclusion Criteria:

* Previous cardiovascular disease
* Chronic renal disease,
* Chronic obstructive pulmonary disease,
* Malignancy,
* Regularly use of statins, antiplatelets or anticoagulants,
* Situations where oral communication cannot be established with the patient
* Situations when coronary angiography (CAG) could not be performed .
* Patients with findings that might be related to previous MI on electrocardiography (ECG) or echocardiography and total occlusion other than 'culprit' lesion and no critical stenosis on CAG
Evaluation of the Causes and Disease Processes of Chronic Lung Disease

Chronic lung diseases are disorders associated with abnormalities in any of the structures involved in the process of breathing and bringing oxygen into the lungs and blood. This includes abnormalities in the airways, lungs, blood vessels in and around the lungs, and the tissue covering the lungs (pleura).

The purpose of this research study is to evaluate patients referred to the Cardiovascular and Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to;

1. Develop a better understanding of the causes and disease processes involved in disorders of the lungs
2. Identify patients eligible to participate in other P-CCMB research studies

The chronic lung diseases are those disorders associated with functional and/or structural derangement to the alveolar structures, airways, pulmonary blood vessels, pleura and/or mediastinum. The purpose of this project is to permit the comprehensive evaluation of patients referred to the Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to: (1) develop an understanding of the etiology and pathogenesis of these disorders; and (2) identify individuals who will be suitable candidates for other NHLBI protocols. Testing and procedures will only be performed when medically indicated for the purposes of making a diagnosis or obtaining information likely to be useful in the management of the subjects' disease or condition.

Eligibility Criteria:
* INCLUSION CRITERIA:

Symptoms consistent with pulmonary disease.

May have family history of lung disease.

Patients with diseases of organs with known association with lung disease.

Ranging in age from 7 to 90 years old.

Pregnant and nursing women may participate in minimal risk procedures

EXCLUSION CRITERIA:

Persons with no clinical evidence of lung disease.
Action of Essential Fatty Acids on the Expression of Antioxidant Genes and Athletic Performance

There are conflicting evidences of the effects of dietary supplementation with polyunsaturated fatty acids (PUFAs) on athletic performance. The investigators working hypothesis is based on the polyunsaturated fatty acids, given its pro-oxidative character and also by its action on transcription factors can modulate the antioxidant response and oxidative damage induced by physical activity.The overall objective of the study is to establish situations improving athletic performance and study the oxidative balance by manipulation of feeding patterns and consumption of nutritional supplements and investigate the involved mechanisms.

There are conflicting evidences of the effects of dietary supplementation with polyunsaturated fatty acids (PUFAs) on athletic performance. The described effects of PUFAs on the fat metabolism may be modulated by the expression and activity of transcription factor genes, suppressing or expressing genes associated with the synthesis and oxidation of fats and in oxidative stress and inflammation.

The investigators' working hypothesis is based on the polyunsaturated fatty acids, given its pro-oxidative character and also by its action on transcription factors can modulate the antioxidant response and oxidative damage induced by physical activity.

In the field of professional sports and leisure use of food and / or antioxidants in the belief that these elements prevent muscle damage is very established. Most studies in athletes supplemented with antioxidant nutrients revealed no significant effects on physical performance, but it has shown that supplements protect against tissue damage induced by exercise. Recent studies have reported that over 35% of the Spanish people eat diets low or very low quality, which is clearly shown that over 10% of Spaniards have poor intakes (\<2/3 IDR) riboflavin (men) , folate (women), vitamin C, vitamin A, vitamin D and vitamin E.

The overall objective of the study is to establish situations improving athletic performance and study the oxidative balance by manipulation of feeding patterns and consumption of nutritional supplements and investigate the involved mechanisms. The aim of this study is to establish scientific basis for design functional foods improving athletic performance and health and avoiding the negative consequences of the oxidative damage induced by overexertion.

Eligibility Criteria:
Inclusion Criteria:

* Ages eligible for study: 16 to 35 years
* Genders eligible for study: Male
* Equilibrate diet
* Physical activity of 1-2 hours daily 5-7 days weekly.
* Body mass index (19-25 kg/m2)

Exclusion Criteria:

* Smokers
Prolactin and FGF21 in Gestational Diabetes Mellitus

Prolactin (PRL) and PRL receptor (PRLR) signaling has been validated to play an important role in the modulation of glucolipid metabolism. However, the role of serum PRL levels in gestational diabetes mellitus (GDM) remains unclear. The investigators aimed to explore the possible influence of serum PRL within or without normal range on the development of GDM.


Eligibility Criteria:
Inclusion Criteria:

* aged 18 to 45 years
* completed a 75-g oral glucose tolerance test (OGTT)
* females with pregnancy

Exclusion Criteria:

* severe liver and renal dysfunction, preexisting heart disease, malignancy, or endocrine diseases such as pituitary adenoma and hypogonadism
* mental illness
* genetic disease
* current or previous treatment that might affect PRL and insulin secretion
* diabetes before pregnancy
* loss to follow-up, or withdrawal from the study
* unable to understand and comply with the study protocol.
Perceptions,Social Representations and Experience of Lyme Borreliosis and Ticks in Adolescents Likely to be Infected and Their Parents

the study is offered to adolescents aged 12 to 17 and their families suspected of or suffering from Lyme barilliosis.

During inclusion, three interviews will be carried out for each family. This choice of the number of interviews per family seems the most appropriate to have a plurality of answers to the questions asked. Thus, these will have a duration of 30 min to 1 hour and will be carried out by an anthropologist. The first interview will be with the teenager. The second interview will then concern the parent(s). Finally, the last appointment will be with the teenager and his parents.

the study is offered to adolescents aged 12 to 17 and their families suspected of or suffering from Lyme barilliosis.

During inclusion, three interviews will be carried out for each family. This choice of the number of interviews per family seems the most appropriate to have a plurality of answers to the questions asked. Thus, these will have a duration of 30 min to 1 hour and will be carried out by an anthropologist. The first interview will be with the teenager. The second interview will then concern the parent(s). Finally, the last appointment will be with the teenager and his parents.

After a few introductory questions concerning the socio-demographic characteristics of adolescents, their medical history and their exposure to ticks, the anthropologist will ask the semi-open questions.

As for the parent(s), the anthropologist will ask them questions directly related to Lyme borreliosis and the tick. Finally, questions will be proposed simultaneously during a joint interview with the teenager and his parents.

Eligibility Criteria:
Inclusion Criteria:

* Be at least 12 years old and maximum 17 years old.
* Be accompanied by a holder of parental authority
* Live in metropolitan France.
* Suspect or have Lyme borreliosis
* Non-objection for participation in the protocol

Exclusion Criteria:

* Refusal of participation of a holder of parental authority and of the adolescent
* Non-mastery of oral French by the teenager or his parents
* Protected persons (patients under guardianship or curatorship, pregnant or nursing women, persons deprived of liberty, person unable to express their non-objection)
Positive Affect Treatment for Adolescents with Early Life Adversity

Youth exposed to early life adversity (ELA) are known to be at greater risk for depression and suicidality and account for almost half of the youth suffering from psychiatric diseases today. Youth exposed to ELA consistently report symptoms of anhedonia as well as dysregulated positive affect. The present project will test the efficacy of PAT in a sample of ELA-exposed adolescents in order to determine whether PAT increases positive affect, and subsequently symptoms of depression. For the initial pilot phase of the investigation, the investigators will recruit up to 30 adolescents exposed to two or more childhood adversities (ACEs) who do not currently have major depressive disorder, and randomize them (1:1) to either participate in PAT or a waitlist control condition. For the second phase of the investigation, the investigators will recruit up to 300 adolescents exposed to two or more childhood adversities (ACEs) who do not currently have major depressive disorder, and randomize them (1:1) to either participate in PAT or supportive psychotherapy. For both phases, at study enrollment, then 4-, 8, and 12-months thereafter the investigators will measure positive affect and depressive symptoms (including anhedonia and reward sensitivity). The results of this study will be used to inform whether PAT has the potential to prevent major depressive episodes among adversity-exposed youth.


Eligibility Criteria:
Inclusion Criteria:

* aged 12-16
* exposed to 2 or more adverse childhood experiences (ACEs)

Exclusion Criteria:

* currently taking an antidepressant or any medications known to influence immune functioning on a daily basis (e.g., steroidal medications to treat asthma or allergies)
* current or past history of manic or psychotic symptoms
* parent-reported diagnosis of intellectual disability or autism spectrum disorder
* chronic medical conditions (e.g., cancer, rheumatoid arthritis, diabetes, multiple sclerosis),
* bleeding disorders such as hemophilia